tranexamic acid




Full Prescribing Info
Tranexamic acid.
Tranexamic acid inhibits fibrinolysis by blocking the binding of plasminogen and plasmin to fibrin, thus preventing dissolution of the haemostatic.
Pharmacologic Classification: Antifibrinolytic.
Pharmacology: Pharmacokinetics: Absorption: Absorbed from the gastrointestinal tract. Bioavailability: Approximately 45% (oral). Time to peak plasma concentration: 2.5 hours after oral administration (range: 1-5 hours).
Distribution: Widely distributed throughout the body. It crosses the placenta and enters breast milk. Volume of distribution: 9-12 L. Plasma protein-binding: Approximately 3%, mainly to plasminogen.
Excretion: Via urine (>95%, as unchanged drug). Elimination half-life: Approximately 2-11 hours.
For short-term management of haemorrhage (localized haemorrhage), menorrhagia, hereditary angioedema, patients with haemophilia undergoing dental extraction.
Dosage/Direction for Use
Menorrhagia (initiated when menstruation has started): 1 g three times daily for up to 4 days; maximum of 4 g daily.
Haemorrhage (for short term use): Adult dose: 1 to 1.5 g 2 to 4 times daily.
Children: 15 to 25 mg/kg 2 to 4 times daily.
Hereditary angioedema: Adult dose: 1 to 1.5 g 2 or 3 times daily.
Children dose: 25 mg/kg 2 or 3 times daily.
Symptoms: Convulsions, dizziness, headache, hypotension, nausea, vomiting.
Management: Supportive treatment.
Hypersensitivity. Active thromboembolic disease (e.g. pulmonary embolism, DVT), history of venous or arterial thrombosis (including retinal vein or artery occlusion), disseminated intravascular coagulation, fibrinolytic conditions after consumption coagulopathy, history of convulsions. Concomitant use with hormonal contraceptives. Severe renal impairment.
Special Precautions
Patients with enormous haematuria from upper urinary tract, history of thromboembolic diseases. Women with subarachnoid haemorrhage or irregular menstrual cycle. Mild to moderate renal impairment. Pregnancy and lactation.
Adverse Reactions
Gastrointestinal disturbances, headache, hypotension, nausea, vomiting and diarrhea.
Drug Interactions
Hemostatic drugs, thrombolytics and estrogens.
Store at temperatures not exceeding 30°C.
MIMS Class
ATC Classification
B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Tarnex FC tab 500 mg
100's (P2,200/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in